MLTX רווח נקי למניה ב-12 החודשים האחרונים moonlaketx.com

The primary risks for MoonLake Immunotherapeutics (MLTX) are centered on the final trial results for sonelokimab and competition with industry behemoths. The company's annual revenue per unit reflects current dynamics, with the value holding around -3.70, supplemented by strategic partnerships with global research centers. Proprietary anti-inflammatory developments create a long-term foundation for extracting high profits from chronic pathologies.
פילוחים אנליטיים ודוחות נתונים של חברת MoonLake Corp (MLTX)

This indicator measures the final return of a single security by allocating the company's total annual net income across all outstanding shares to assess real capital efficiency. By analyzing the rolling earnings per share (EPS) metric, an investor can see how the clinical research and manufacturing outsourcing strategy of MoonLake Immunotherapeutics (MLTX) impacts cost reduction and the bottom line.